Kyverna therapeutics provides business update and reports second quarter 2024 financial results

Actively recruiting clinical trials in neurology and rheumatology with kyv-101 no severe icans or crs reported in first 36 autoimmune disease patients treated with kyv-101 received fda rmat designation for kyv-101 for treatment of patients with stiff-person syndrome received fda rmat designation for kyv-101 for treatment of patients with myasthenia gravis reported clinical experience with first kyv-101 patient disease-free at 1 year after treatment emeryville, calif. , aug. 12, 2024 /prnewswire/ -- kyverna therapeutics, inc. (nasdaq: kytx), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today reported its business highlights and financial results for the second quarter ended june 30, 2024.
KYTX Ratings Summary
KYTX Quant Ranking